NCT Number stringlengths 11 11 | Study Title stringlengths 18 300 | Study URL stringlengths 44 44 | Study Status stringclasses 13
values | Conditions stringlengths 3 11.1k ⌀ | Interventions stringlengths 5 1.2k ⌀ | Sponsor stringlengths 3 121 | Collaborators stringlengths 2 3.21k ⌀ | Study Type stringclasses 3
values |
|---|---|---|---|---|---|---|---|---|
NCT05457309 | Construction and Effect Evaluation of Malignant Fungating Wounds Care Regimen for Breast Cancer Patients | https://clinicaltrials.gov/study/NCT05457309 | RECRUITING | Malignant Fungating Wound | PROCEDURE: malignant fungating wounds care regimen | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | null | INTERVENTIONAL |
NCT05596409 | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | https://clinicaltrials.gov/study/NCT05596409 | RECRUITING | Metastatic Breast Cancer | DRUG: Elacestrant | Stemline Therapeutics, Inc. | null | INTERVENTIONAL |
NCT05428709 | Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology | https://clinicaltrials.gov/study/NCT05428709 | TERMINATED | Breast Cancer | BEHAVIORAL: Acute Exercise | Milton S. Hershey Medical Center | null | INTERVENTIONAL |
NCT00343109 | Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer | https://clinicaltrials.gov/study/NCT00343109 | COMPLETED | HER2-positive Breast Cancer|Male Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | BIOLOGICAL: HER-2/neu intracellular domain protein|PROCEDURE: leukapheresis|OTHER: laboratory biomarker analysis|BIOLOGICAL: sargramostim|OTHER: immunologic technique|BIOLOGICAL: synthetic tumor-associated peptide vaccine therapy | University of Washington | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT04093609 | XIST Gene Deletion in Breast Cancer Therapy | https://clinicaltrials.gov/study/NCT04093609 | UNKNOWN | Breast Cancer | GENETIC: XIST gene deletion | Assiut University | null | OBSERVATIONAL |
NCT00185809 | Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study | https://clinicaltrials.gov/study/NCT00185809 | COMPLETED | Breast Cancer | null | Stanford University | Susan G. Komen Breast Cancer Foundation | OBSERVATIONAL |
NCT02751606 | Nano MRI on 7 Tesla in Rectal and Breast Cancer | https://clinicaltrials.gov/study/NCT02751606 | UNKNOWN | Rectal Neoplasms|Breast Neoplasms | DRUG: ferumoxtran-10|DEVICE: 7 Tesla MRI|DEVICE: 3 Tesla MRI | Radboud University Medical Center | null | INTERVENTIONAL |
NCT02599506 | Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment | https://clinicaltrials.gov/study/NCT02599506 | COMPLETED | Breast Cancer | null | University of St Andrews | NHS Lothian | OBSERVATIONAL |
NCT02131506 | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer | https://clinicaltrials.gov/study/NCT02131506 | TERMINATED | HER-2 Positive Breast Cancer|Malignant Neoplasm of Breast | DRUG: Lapatinib, Caelyx | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | null | INTERVENTIONAL |
NCT01391806 | The Impact of Preoperative Breast MRI in Patients With Breast Cancer Selected for Breast Conserving Surgery | https://clinicaltrials.gov/study/NCT01391806 | COMPLETED | Breast Cancer | null | Nordlandssykehuset HF | null | OBSERVATIONAL |
NCT01736306 | Biomarkers for Breast Cancer Risk in African American Women | https://clinicaltrials.gov/study/NCT01736306 | COMPLETED | Breast Cancer | null | National Cancer Institute (NCI) | null | OBSERVATIONAL |
NCT04402606 | Study on Skin Toxicities Induced by Cancer Treatments | https://clinicaltrials.gov/study/NCT04402606 | RECRUITING | Solid Tumor, Adult|Breast Cancer|Lung Cancer | OTHER: Evaluation on skin toxicities | Institut Curie | null | INTERVENTIONAL |
NCT01194427 | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | https://clinicaltrials.gov/study/NCT01194427 | TERMINATED | Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Invasive Breast Cancer | DRUG: Vorinostat and Tamoxifen | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Merck Sharp & Dohme LLC | INTERVENTIONAL |
NCT04711109 | Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | https://clinicaltrials.gov/study/NCT04711109 | RECRUITING | BRCA1 Mutation|Breast Cancer|Breast Diseases|Breast Neoplasms|Breast Carcinoma|Neoplasms | DRUG: Denosumab|DRUG: Placebo|OTHER: Quality-of-Life Assessment | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI)|Austrian Breast & Colorectal Cancer Study Group (ABCSG) | INTERVENTIONAL |
NCT00968409 | Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP) | https://clinicaltrials.gov/study/NCT00968409 | COMPLETED | Breast Cancer | RADIATION: PET|OTHER: Laboratory Testing|OTHER: Safety Testing|DRUG: F18-FFNP | Washington University School of Medicine | null | INTERVENTIONAL |
NCT00691509 | Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer | https://clinicaltrials.gov/study/NCT00691509 | UNKNOWN | Breast Cancer | GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: high performance liquid chromatography|OTHER: laboratory biomarker analysis|OTHER: mass spectrometry|OTHER: questionnaire administration | University College London Hospitals | null | OBSERVATIONAL |
NCT06154109 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | https://clinicaltrials.gov/study/NCT06154109 | NOT_YET_RECRUITING | Triple Negative Breast Neoplasms | DRUG: Xiaopi granules|DRUG: Xiaopi decoction|DRUG: Placebo | Zhiyu Wang | null | INTERVENTIONAL |
NCT01765309 | A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders | https://clinicaltrials.gov/study/NCT01765309 | COMPLETED | Breast Cancer | PROCEDURE: Bilateral mastectomy with reconstruction | University of Colorado, Denver | null | INTERVENTIONAL |
NCT00523809 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | https://clinicaltrials.gov/study/NCT00523809 | TERMINATED | Breast Cancer|Ovarian Cancer | DRUG: Bevacizumab|PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Thymoglobulin | M.D. Anderson Cancer Center | null | INTERVENTIONAL |
NCT00291109 | An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg | https://clinicaltrials.gov/study/NCT00291109 | COMPLETED | Breast Cancer | DRUG: letrozole 2.5 mg | University of Kansas | null | OBSERVATIONAL |
NCT01861509 | BP-C1 in Metastatic Breast Cancer Patients | https://clinicaltrials.gov/study/NCT01861509 | COMPLETED | Metastatic Breast Cancer|Stage IV Breast Cancer | DRUG: BP-C1 | Meabco A/S | null | INTERVENTIONAL |
NCT04137406 | Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis | https://clinicaltrials.gov/study/NCT04137406 | UNKNOWN | Breast Cancer|Lymph Node Metastases | null | Peking University People's Hospital | null | OBSERVATIONAL |
NCT01954706 | Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT01954706 | TERMINATED | Breast Cancer|Sarcopenia | OTHER: Structured Exercise|OTHER: Usual Care | Baltimore VA Medical Center | National Institute on Aging (NIA) | INTERVENTIONAL |
NCT01641406 | "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" | https://clinicaltrials.gov/study/NCT01641406 | UNKNOWN | Infiltrating Duct and Lobular Carcinoma In Situ|Invasive Lobular Breast Carcinoma|Inflammatory Breast Carcinoma | DRUG: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|DRUG: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|DRUG: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab | Auxilio Mutuo Cancer Center | null | INTERVENTIONAL |
NCT04197206 | Ultrasound Guided Costotransverse Block for Breast Cancer Surgery | https://clinicaltrials.gov/study/NCT04197206 | COMPLETED | Postoperative Pain | OTHER: costotransverse block | Cigli Regional Training Hospital | null | INTERVENTIONAL |
NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours | https://clinicaltrials.gov/study/NCT03518606 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumours|Breast Cancer|Head and Neck Cancer|Cervix Cancer|Prostate Cancer | DRUG: Durvalumab + Tremelimumab + metronomic Vinorelbine | UNICANCER | National Cancer Institute, France|AstraZeneca|Pierre Fabre Laboratories | INTERVENTIONAL |
NCT03300206 | A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System | https://clinicaltrials.gov/study/NCT03300206 | COMPLETED | Breast Cancer Female | DEVICE: Breast Biopsy | Hologic, Inc. | null | OBSERVATIONAL |
NCT01801527 | Telehealth System to Improve Quality of Life in Breast Cancer Survivors | https://clinicaltrials.gov/study/NCT01801527 | COMPLETED | Breast Cancer | BEHAVIORAL: Telerehabilitation group | Universidad de Granada | Carlos III Health Institute | INTERVENTIONAL |
NCT02238509 | Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | https://clinicaltrials.gov/study/NCT02238509 | UNKNOWN | Metastatic Breast Cancer | DRUG: Lapatinib|DRUG: Trastuzumab | Consorzio Oncotech | Clinical Research Technology S.r.l. | INTERVENTIONAL |
NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors | https://clinicaltrials.gov/study/NCT00739609 | TERMINATED | Breast Cancer|Lung Cancer|Melanoma|Pancreatic Cancer|Solid Tumors | DRUG: 1-methyl-D-tryptophan | NewLink Genetics Corporation | null | INTERVENTIONAL |
NCT00899509 | Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT00899509 | COMPLETED | Breast Cancer | OTHER: laboratory biomarker analysis | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | OBSERVATIONAL |
NCT00963209 | Tamoxifen Citrate in Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT00963209 | UNKNOWN | Breast Cancer | DRUG: tamoxifen citrate|OTHER: laboratory biomarker analysis|OTHER: pharmacological study | Centre Hospitalier Universitaire Vaudois | null | INTERVENTIONAL |
NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | https://clinicaltrials.gov/study/NCT02003209 | ACTIVE_NOT_RECRUITING | HER2-Positive Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | DRUG: Aromatase Inhibition Therapy|DRUG: Carboplatin|OTHER: Cytology Specimen Collection Procedure|DRUG: Docetaxel|DRUG: Goserelin Acetate|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|PROCEDURE: Therapeutic Conventional Surgery|BIOLOGICAL: Trastuzumab|RADIATION: Whole Br... | National Cancer Institute (NCI) | NRG Oncology | INTERVENTIONAL |
NCT00379106 | Arm Function and Quality of Life Following Mastectomy. | https://clinicaltrials.gov/study/NCT00379106 | COMPLETED | Breast Cancer | PROCEDURE: Arm exercises.|PROCEDURE: Arm Exercises | University of New Mexico | null | INTERVENTIONAL |
NCT00001806 | Methods in Education for Breast Cancer Genetics | https://clinicaltrials.gov/study/NCT00001806 | COMPLETED | Breast Cancer|Ovarian Cancer | OTHER: Genetic Education and Counseling|OTHER: Genetic Education and Counseling | National Cancer Institute (NCI) | null | INTERVENTIONAL |
NCT01621906 | 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain | https://clinicaltrials.gov/study/NCT01621906 | COMPLETED | Metastatic Breast Cancer to the Brain | DEVICE: 18F-FLT-PET Imaging|DEVICE: 18F-FLT-PET Imaging | Memorial Sloan Kettering Cancer Center | null | INTERVENTIONAL |
NCT00003906 | Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women | https://clinicaltrials.gov/study/NCT00003906 | COMPLETED | Breast Cancer | DRUG: Raloxifene|DRUG: Tamoxifen | NSABP Foundation Inc | National Cancer Institute (NCI)|Eli Lilly and Company|AstraZeneca | INTERVENTIONAL |
NCT06081127 | Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function | https://clinicaltrials.gov/study/NCT06081127 | RECRUITING | Breast Cancer | OTHER: MOve-ABC|OTHER: Enhanced Usual Care | Northwestern University | Northwestern Medicine | INTERVENTIONAL |
NCT01262027 | TKI258 for Metastatic Inflammatory Breast Cancer Patients | https://clinicaltrials.gov/study/NCT01262027 | COMPLETED | Breast Cancer | DRUG: Dovitinib | M.D. Anderson Cancer Center | Novartis | INTERVENTIONAL |
NCT04554927 | Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer | https://clinicaltrials.gov/study/NCT04554927 | RECRUITING | Web-application|Breast Cancer|Hormono Therapy | OTHER: WEB-Application|OTHER: Standard accompaniment | Centre Francois Baclesse | null | INTERVENTIONAL |
NCT03442127 | Facilitating Oncology Patient-Clinician Communication Via E-health Innovations | https://clinicaltrials.gov/study/NCT03442127 | COMPLETED | Breast Cancer | BEHAVIORAL: CaringGuidance™ After Breast Cancer Diagnosis | University of Nebraska | null | INTERVENTIONAL |
NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) | https://clinicaltrials.gov/study/NCT00900627 | COMPLETED | Neoplasms|Breast Neoplasms|Breast Cancer | DRUG: AZD8931|DRUG: Paclitaxel|DRUG: Placebo | AstraZeneca | null | INTERVENTIONAL |
NCT00179309 | Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer | https://clinicaltrials.gov/study/NCT00179309 | COMPLETED | Breast Cancer | DRUG: Docetaxel|BIOLOGICAL: PANVAC-V|BIOLOGICAL: PANVAC-F|BIOLOGICAL: Sargramostim | National Cancer Institute (NCI) | null | INTERVENTIONAL |
NCT05207709 | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype | https://clinicaltrials.gov/study/NCT05207709 | RECRUITING | Metastatic Breast Cancer | DRUG: Ribociclib + Letrozole OR Fulvestrant|DRUG: Palbociclib + Letrozole OR Fulvestrant|DRUG: Paclitaxel +/- Tislelizumab | SOLTI Breast Cancer Research Group | Novartis|Alliance Foundation Trials, LLC. | INTERVENTIONAL |
NCT00908609 | Optical Tomography With Ultrasound Guidance | https://clinicaltrials.gov/study/NCT00908609 | COMPLETED | Breast Cancer | null | UConn Health | National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Donaghue Medical Research Foundation | OBSERVATIONAL |
NCT05747209 | EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Breast CA | https://clinicaltrials.gov/study/NCT05747209 | RECRUITING | Breast Cancer Female | OTHER: Observation of Exercise Program Adherence | Colin Champ, MD | null | OBSERVATIONAL |
NCT00436709 | Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer | https://clinicaltrials.gov/study/NCT00436709 | UNKNOWN | Breast Cancer | BIOLOGICAL: bevacizumab|BIOLOGICAL: pegfilgrastim|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: paclitaxel albumin-stabilized nanoparticle formulation|OTHER: flow cytometry|OTHER: immunoenzyme technique|OTHER: immunologic technique|OTHER: laboratory biomarker analysis|PROCEDURE: adjuvant therapy|PROCEDUR... | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT03266809 | CARdiac Function Evaluation in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT03266809 | COMPLETED | Breast Cancer Female | null | Swansea University | Abertawe Bro Morgannwg University Health Board | OBSERVATIONAL |
NCT00880009 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | https://clinicaltrials.gov/study/NCT00880009 | TERMINATED | Breast Cancer | DRUG: Bosutinib|DRUG: Letrozole|DRUG: Letrozole | Pfizer | null | INTERVENTIONAL |
NCT04106609 | Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients | https://clinicaltrials.gov/study/NCT04106609 | UNKNOWN | Breast Cancer | OTHER: Supervised, individualized exercise oncology program|OTHER: Current standard of care | Karen Wonders | null | INTERVENTIONAL |
NCT03495609 | Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers | https://clinicaltrials.gov/study/NCT03495609 | COMPLETED | hCG|BRCA1 Mutation|BRCA2 Mutation | DRUG: Ovitrelle | University Hospital, Ghent | Fox Chase Cancer Center|Ziekenhuis Oost-Limburg | INTERVENTIONAL |
NCT04230109 | Sacituzumab Govitecan In TNBC | https://clinicaltrials.gov/study/NCT04230109 | RECRUITING | Invasive Breast Cancer|Triple Negative Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|HER2-negative Breast Cancer | DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab | Aditya Bardia | Gilead Sciences | INTERVENTIONAL |
NCT00639106 | Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial | https://clinicaltrials.gov/study/NCT00639106 | COMPLETED | Breast Cancer | PROCEDURE: Alloderm, Questionnaires|PROCEDURE: Without ALLODERM, Questionnaires | Memorial Sloan Kettering Cancer Center | University of Michigan|University of North Carolina, Chapel Hill | INTERVENTIONAL |
NCT00900406 | Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant | https://clinicaltrials.gov/study/NCT00900406 | COMPLETED | Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor | GENETIC: gene expression analysis|GENETIC: microarray analysis|GENETIC: polymorphism analysis|GENETIC: proteomic profiling|OTHER: flow cytometry|OTHER: immunologic technique|OTHER: laboratory biomarker analysis|PROCEDURE: biopsy | Vanderbilt-Ingram Cancer Center | National Cancer Institute (NCI) | OBSERVATIONAL |
NCT03132506 | E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research | https://clinicaltrials.gov/study/NCT03132506 | UNKNOWN | Breast Cancer Metastatic | OTHER: patient-reported-outcomes | University Women's Hospital Tübingen | National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany|Department of Gynecology and Obstetrics, University Hospital Heidelberg, Germany|Department of Gynecology and Obstetrics, University Hospital Erlangen, Germany | OBSERVATIONAL |
NCT04882306 | The ABC Study: Assessment of Breast Density Classification | https://clinicaltrials.gov/study/NCT04882306 | RECRUITING | Breast Cancer | DEVICE: Bilateral MARIA scan | Micrima, Ltd. | null | INTERVENTIONAL |
NCT00601406 | Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | https://clinicaltrials.gov/study/NCT00601406 | UNKNOWN | Breast Cancer|Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer|Prostate Cancer|Sarcoma|Vaginal Cancer|Vulvar Cancer | GENETIC: gene expression analysis|GENETIC: gene rearrangement analysis|GENETIC: polymorphism analysis|OTHER: laboratory biomarker analysis|RADIATION: radiation therapy | The Christie NHS Foundation Trust | null | INTERVENTIONAL |
NCT05700006 | Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging | https://clinicaltrials.gov/study/NCT05700006 | RECRUITING | Breast Neoplasm Female|Arthralgia|Aging | DRUG: Aromatase inhibitor | University of Michigan | null | OBSERVATIONAL |
NCT03552406 | Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT03552406 | UNKNOWN | Solid Tumor | BIOLOGICAL: ISU104|DRUG: Cetuximab | ISU Abxis Co., Ltd. | null | INTERVENTIONAL |
NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | https://clinicaltrials.gov/study/NCT03971409 | RECRUITING | Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma | BIOLOGICAL: Anti-OX40 Antibody PF-04518600|DRUG: Avelumab|DRUG: Binimetinib|BIOLOGICAL: Utomilumab|DRUG: Liposomal Doxorubicin|DRUG: Sacituzumab Govitecan | Hope Rugo, MD | Translational Breast Cancer Research Consortium|Hoosier Cancer Research Network|Array BioPharma|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|Gilead Sciences | INTERVENTIONAL |
NCT04482309 | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | https://clinicaltrials.gov/study/NCT04482309 | ACTIVE_NOT_RECRUITING | Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer|Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer | DRUG: Trastuzumab deruxtecan | AstraZeneca | Daiichi Sankyo Co., Ltd. | INTERVENTIONAL |
NCT04014309 | Accessible Cancer Care to Enable Support for Survivors Programme | https://clinicaltrials.gov/study/NCT04014309 | UNKNOWN | Survivorship|Breast Cancer|Gynecologic Cancer | OTHER: Supportive and survivorship care program|OTHER: Usual care | National University of Singapore | National Cancer Centre, Singapore | INTERVENTIONAL |
NCT02316509 | A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | https://clinicaltrials.gov/study/NCT02316509 | COMPLETED | Breast Cancer | DRUG: GDC-0927 | Genentech, Inc. | Seragon Pharmaceuticals | INTERVENTIONAL |
NCT04217109 | Transcutaneous Breast Cancer Diagnosis by Canine Odorology | https://clinicaltrials.gov/study/NCT04217109 | COMPLETED | Breast Cancer | DIAGNOSTIC_TEST: Odour sampling | Institut Curie | null | INTERVENTIONAL |
NCT05595109 | Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT05595109 | ENROLLING_BY_INVITATION | Breast Cancer|Peripheral Neuropathy|Cardiac Toxicities|Hepatic Toxicity|Cognitive Impairment | DRUG: Silymarin|DRUG: Placebo | Tanta University | null | INTERVENTIONAL |
NCT01688609 | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT01688609 | COMPLETED | HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer | DRUG: lapatinib ditosylate|DRUG: paclitaxel|BIOLOGICAL: trastuzumab|PROCEDURE: therapeutic conventional surgery|OTHER: pharmacological study|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | null | INTERVENTIONAL |
NCT01804309 | Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer | https://clinicaltrials.gov/study/NCT01804309 | COMPLETED | Breast Cancer | PROCEDURE: Sentinel lymph node biopsy (SLNB) | National Institute of Oncology, Hungary | null | OBSERVATIONAL |
NCT04817709 | Development of a Patient Decision Aid for Women Considering Breast Reconstruction | https://clinicaltrials.gov/study/NCT04817709 | COMPLETED | Breast Carcinoma | OTHER: Educational Intervention|OTHER: Usual Care|OTHER: Media Intervention|OTHER: Medical Chart Review|OTHER: Questionnaire Administration | M.D. Anderson Cancer Center | null | OBSERVATIONAL |
NCT02505906 | Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique | https://clinicaltrials.gov/study/NCT02505906 | COMPLETED | Breast Cancer | RADIATION: Simultaneous Integrated Boost Technique | University Medical Center Groningen | null | OBSERVATIONAL |
NCT02557906 | Evaluating Outcomes of Immediate Breast Reconstruction (POBRAD-M) | https://clinicaltrials.gov/study/NCT02557906 | UNKNOWN | Breast Neoplasms|Breast Diseases | PROCEDURE: Breast reconstruction - implant and an ADM (SurgiMend)|PROCEDURE: Breast reconstruction- autologous tissue|PROCEDURE: Breast reconstruction- implant + dermal sling/LD flap | King's College London | Guy's and St Thomas' NHS Foundation Trust|Integra LifeSciences Corporation | INTERVENTIONAL |
NCT04986306 | The Validation of Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT04986306 | UNKNOWN | Breast Cancer|Sentinel Lymph Node Biopsy|Neoadjuvant Therapy | PROCEDURE: SLNB + ALND | National Cheng-Kung University Hospital | null | OBSERVATIONAL |
NCT00407706 | Using Test of SCM for Detection Breast Cancer | https://clinicaltrials.gov/study/NCT00407706 | UNKNOWN | Malignant Breast Cancer, Benign Breast Lesions | PROCEDURE: blood test | Ziv Hospital | null | OBSERVATIONAL |
NCT00659906 | Optimizing Body Composition & Health After Breast Cancer | https://clinicaltrials.gov/study/NCT00659906 | COMPLETED | Breast Neoplasm|Osteoporosis, Postmenopausal | BEHAVIORAL: Resistance Exercise|BEHAVIORAL: Flexibility Training | OHSU Knight Cancer Institute | American Cancer Society, Inc. | INTERVENTIONAL |
NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | https://clinicaltrials.gov/study/NCT00878709 | COMPLETED | Breast Cancer | DRUG: neratinib|OTHER: placebo | Puma Biotechnology, Inc. | null | INTERVENTIONAL |
NCT03766009 | Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making | https://clinicaltrials.gov/study/NCT03766009 | ACTIVE_NOT_RECRUITING | Breast Cancer Stage 0|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III | OTHER: Usual Care|OTHER: Web-based decision aid | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI)|Agency for Healthcare Research and Quality (AHRQ) | INTERVENTIONAL |
NCT03584009 | A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy | https://clinicaltrials.gov/study/NCT03584009 | TERMINATED | Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer | DRUG: Venetoclax|DRUG: Fulvestrant | Hoffmann-La Roche | null | INTERVENTIONAL |
NCT01185509 | Trastuzumab and Vinorelbine in Advanced Breast Cancer | https://clinicaltrials.gov/study/NCT01185509 | TERMINATED | Breast Cancer|Metastatic Breast Cancer | DRUG: trastuzumab|DRUG: vinorelbine | Dana-Farber Cancer Institute | Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc. | INTERVENTIONAL |
NCT04495309 | Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer | https://clinicaltrials.gov/study/NCT04495309 | RECRUITING | Metastatic Breast Cancer | RADIATION: Metastases-directed Radiotherapy | University Hospital Schleswig-Holstein | null | INTERVENTIONAL |
NCT05011409 | Prevalence of Depression and Anxiety Among Breast Cancer Patients | https://clinicaltrials.gov/study/NCT05011409 | COMPLETED | Depression|Anxiety|Breast Cancer | null | Kazakh Medical University of Continuing Education | University of Malaya | OBSERVATIONAL |
NCT00737009 | An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment | https://clinicaltrials.gov/study/NCT00737009 | COMPLETED | Breast Cancer | null | AstraZeneca | null | OBSERVATIONAL |
NCT03811509 | Breast Cancer Women on Aromatase Inhibitors Treatment | https://clinicaltrials.gov/study/NCT03811509 | UNKNOWN | Osteoporosis|Osteoporosis Fracture|Arthralgia Generalized | DRUG: bisphosphonate | Parc de Salut Mar | Instituto de Salud Carlos III | INTERVENTIONAL |
NCT02208206 | Analysis of Markers in the Blood Correlated With Neuropathic Pain | https://clinicaltrials.gov/study/NCT02208206 | COMPLETED | Neuropathy | null | Christoph Stein, MD | deCODE genetics | OBSERVATIONAL |
NCT02273206 | Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women | https://clinicaltrials.gov/study/NCT02273206 | COMPLETED | Depression|Breast Cancer Screening|Cervical Cancer Screening|Colorectal Cancer Screening | BEHAVIORAL: Prevention Care Management for Depression and Cancer Screening|BEHAVIORAL: Prevention Care Management for Cancer Screening | Clinical Directors Network | null | INTERVENTIONAL |
NCT01395706 | ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes | https://clinicaltrials.gov/study/NCT01395706 | UNKNOWN | Malignant Neoplasm of Breast | PROCEDURE: ICG Fluorescence technique | Pulsion Medical Systems SE | null | INTERVENTIONAL |
NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | https://clinicaltrials.gov/study/NCT06195306 | NOT_YET_RECRUITING | Breast Atypical Hyperplasia|Breast Carcinoma|Breast Ductal Carcinoma In Situ|Breast Lobular Carcinoma In Situ | PROCEDURE: Biospecimen Collection|PROCEDURE: Mammography|DRUG: Omega-3-Acid Ethyl Esters|OTHER: Questionnaire Administration|PROCEDURE: Random Periareolar Fine-Needle Aspiration|DRUG: Tamoxifen | National Cancer Institute (NCI) | null | INTERVENTIONAL |
NCT05156606 | Testosterone & Tamoxifen Trial | https://clinicaltrials.gov/study/NCT05156606 | RECRUITING | Male Breast Cancer | DRUG: AndroGel | University Medical Center Groningen | null | INTERVENTIONAL |
NCT00810706 | Adjuvant Post-Tamoxifen Exemestane Trial | https://clinicaltrials.gov/study/NCT00810706 | TERMINATED | Breast Cancer | DRUG: exemestane | Hellenic Breast Surgeons Society | null | INTERVENTIONAL |
NCT05878106 | Creatine Supplementation and Resistance Training in Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT05878106 | NOT_YET_RECRUITING | Breast Cancer|Supplementation|Resistance Training|Physical Performance|Quality of Life | DIETARY_SUPPLEMENT: Creatine supplementation|OTHER: Resistance training | University of Deusto | Hospital de Cruces|Hospital de Basurto|Poznan University of Medical Sciences|Hospital Universitario de Burgos|Dynamical Business & Science Society - DBSS|University of Calabria | INTERVENTIONAL |
NCT00307606 | Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma | https://clinicaltrials.gov/study/NCT00307606 | UNKNOWN | Breast Neoplasms|Mastectomy | DRUG: Solu-medrol 125 mg | Herlev Hospital | null | INTERVENTIONAL |
NCT02689427 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | https://clinicaltrials.gov/study/NCT02689427 | COMPLETED | Invasive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Can... | PROCEDURE: Axillary Lymph Node Dissection|DRUG: Enzalutamide|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Lymph Node Biopsy|DRUG: Paclitaxel|PROCEDURE: Therapeutic Conventional Surgery | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT00543127 | Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | https://clinicaltrials.gov/study/NCT00543127 | TERMINATED | Breast Cancer | DRUG: Fulvestrant|DRUG: Anastrozole | Spanish Breast Cancer Research Group | AstraZeneca | INTERVENTIONAL |
NCT00381927 | Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development | https://clinicaltrials.gov/study/NCT00381927 | COMPLETED | Breast Cancer | BEHAVIORAL: Physician Counseling | Baystate Medical Center | null | OBSERVATIONAL |
NCT00627627 | A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer | https://clinicaltrials.gov/study/NCT00627627 | WITHDRAWN | Breast Cancer | DRUG: IPI-504 | MedImmune LLC | null | INTERVENTIONAL |
NCT05817227 | Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer. | https://clinicaltrials.gov/study/NCT05817227 | RECRUITING | Breast Cancer | null | National Cancer Institute, Naples | null | OBSERVATIONAL |
NCT02754427 | Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer | https://clinicaltrials.gov/study/NCT02754427 | COMPLETED | Breast Cancer | BEHAVIORAL: Prospective Surveillance Group|BEHAVIORAL: Education Group | University of British Columbia | null | INTERVENTIONAL |
NCT05138627 | The Effect of Oral Cryotherapy on Anticipatory, Acute and Late Nausea and Vomiting in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT05138627 | COMPLETED | Breast Cancer | OTHER: oral cryotherapy | Berna KURT | null | INTERVENTIONAL |
NCT01344109 | A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | https://clinicaltrials.gov/study/NCT01344109 | WITHDRAWN | Breast Neoplasms | null | Leo W. Jenkins Cancer Center | null | OBSERVATIONAL |
NCT00096109 | Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT00096109 | TERMINATED | Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | DRUG: tanespimycin|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | null | INTERVENTIONAL |
NCT00002509 | High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer | https://clinicaltrials.gov/study/NCT00002509 | COMPLETED | Breast Cancer | BIOLOGICAL: filgrastim|DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide|DRUG: mesna|PROCEDURE: autologous bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation | Temple University | Fox Chase Cancer Center | INTERVENTIONAL |
NCT02386709 | Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer | https://clinicaltrials.gov/study/NCT02386709 | ACTIVE_NOT_RECRUITING | FDG PET | DEVICE: FDG PET | Centre Georges Francois Leclerc | null | INTERVENTIONAL |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.